# Advances in clinical application on nursing intervention for ribavirin-associated adverse events

**Authors:** Li-Li Jiang, Qing Wang, Jia-Xin Zhang, Jing-Hui Fan, Jing Li

PMC · DOI: 10.3389/fphar.2025.1596007 · Frontiers in Pharmacology · 2025-10-28

## TL;DR

This paper discusses how nursing interventions can help manage side effects of ribavirin, improving treatment outcomes and patient quality of life.

## Contribution

The paper highlights the role of nursing in managing ribavirin-associated adverse events and suggests future research directions for standardized protocols.

## Key findings

- Nursing interventions significantly improve treatment efficacy and quality of life for patients on ribavirin.
- Challenges include patient variability and lack of evidence-based guidelines for managing ribavirin side effects.
- Future research should focus on standardized protocols and intelligent nursing approaches.

## Abstract

Ribavirin is a broad-spectrum antiviral drug used to treat chronic hepatitis C, respiratory syncytial virus infections, and other viral diseases. However, its clinical use is often limited by adverse events, including hemolytic anemia, gastrointestinal disturbances, and neurological symptoms, which negatively affect treatment adherence and patient well-being. Nursing interventions are essential in mitigating these adverse events through early assessment, symptom management, patient education, and multidisciplinary collaboration, ultimately improving patient outcomes. Current evidence shows that nursing interventions significantly improve treatment efficacy and quality of life. However, challenges persist, such as individual patient variability, resource constraints, and insufficient evidence-based guidelines. Future research should focus on establishing standardized nursing protocols, conducting multicenter clinical studies, exploring intelligent nursing approaches, and enhancing nursing expertise to optimize ribavirin-related adverse event management.

## Linked entities

- **Chemicals:** ribavirin (PubChem CID 37542)
- **Diseases:** chronic hepatitis C (MONDO:0005231)

## Full-text entities

- **Diseases:** viral diseases (MESH:D014777), respiratory syncytial virus infections (MESH:D018357), hepatitis C (MESH:D019698), gastrointestinal disturbances (MESH:D005767), hemolytic anemia (MESH:D000743), neurological symptoms (MESH:D009461)
- **Chemicals:** Ribavirin (MESH:D012254)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12602387/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12602387/full.md

## References

45 references — full list in the complete paper: https://tomesphere.com/paper/PMC12602387/full.md

---
Source: https://tomesphere.com/paper/PMC12602387